Dr. Numb

Lidocaine And Benzethonium Chloride Cream


Shinpharma Inc
Human Otc Drug
NDC 69903-002
Dr. Numb also known as Lidocaine And Benzethonium Chloride Cream is a human otc drug labeled by 'Shinpharma Inc'. National Drug Code (NDC) number for Dr. Numb is 69903-002. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Dr. Numb drug includes Benzethonium Chloride - .25 mg/50g Lidocaine - 4 mg/50g . The currest status of Dr. Numb drug is Active.

Drug Information:

Drug NDC: 69903-002
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Dr. Numb
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lidocaine And Benzethonium Chloride Cream
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Shinpharma Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BENZETHONIUM CHLORIDE - .25 mg/50g
LIDOCAINE - 4 mg/50g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 12 Sep, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 08 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Shinpharma Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000175682
M0000897
N0000175426
N0000175976
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:PH41D05744
98PI200987
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Amide Local Anesthetic [EPC]
Antiarrhythmic [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Local Anesthesia [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Amides [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Amide Local Anesthetic [EPC]
Amides [CS]
Antiarrhythmic [EPC]
Local Anesthesia [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
69903-002-501 TUBE in 1 CARTRIDGE (69903-002-50) / 50 g in 1 TUBE12 Sep, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose external analgesic and first aid antiseptic

Product Elements:

Dr. numb lidocaine and benzethonium chloride cream allantoin aloe vera leaf arnica montana flower benzyl alcohol glycerin lauramidopropyl betaine leuconostoc/radish root ferment filtrate 3-((l-menthyl)oxy)propane-1,2-diol phenoxyethanol selaginella lepidophylla sodium hydroxide water lidocaine lidocaine benzethonium chloride benzethonium

Indications and Usage:

Uses can be used instead of soap and water to help clean minor cuts, scrapes, and burns for the temporary relief of discomfort and pain associated with dermal procedures such as tattoo removal, dermarolling, electrolysis, microblading, and piercing temporarily relieves pain and itch while helping to prevent infection.

Warnings:

Warnings for external use only avoid contact with eyes ​​ do not use do not use in large quantities particularly over raw surfaces or blistered area do not exceed the recommended dosage unless directed by a doctor in the eyes or apply over large areas of body longer than one week unless directed by a doctor ask a doctor before use if you have deep or puncture wounds, animal bites or serious burns stop the use and consult doctor if: condition worsenss or symptoms persist for more than 7 days or clear up and occur again within few days. keep out of reach of children if swallowed, get medical help or contact a poison control center right away

Do Not Use:

Warnings for external use only avoid contact with eyes ​​ do not use do not use in large quantities particularly over raw surfaces or blistered area do not exceed the recommended dosage unless directed by a doctor in the eyes or apply over large areas of body longer than one week unless directed by a doctor ask a doctor before use if you have deep or puncture wounds, animal bites or serious burns stop the use and consult doctor if: condition worsenss or symptoms persist for more than 7 days or clear up and occur again within few days. keep out of reach of children if swallowed, get medical help or contact a poison control center right away

Dosage and Administration:

Directions use dr.numb® topical anesthetic foam soap to cleanse the targeted area. shake well before each use. apply 2 to 3 pumps of foam soap andgently rub into the skin. leave it onfor 5 to 10 minutes. rinse off gentlywith running water or wipe with cleanpaper towel. use before, during andafter the procedure. make sure tocover the bottle tightly when not inuse, otherwise, the anesthetic effect will be lessened. adults and children two years old and older: use to clean minor cuts, scrapes, and burns by thoroughly washing with water. rinse and air dry. use no more than three times daily. children under two years of age, ask a doctor.

Stop Use:

Stop the use and consult doctor if: condition worsenss or symptoms persist for more than 7 days or clear up and occur again within few days.

Package Label Principal Display Panel:

Principal display panel ndc 69903-002-50 dr.numb topical anesthetic foam soap 4% lidocaine 0.25% benzethonium chloride disinfect desensitize and relax 1.7 oz label

Further Questions:

Question or comments? call weekdays 9 am to 6 pm pst at 1-877-786-2001 or email us at support@drnumb.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.